Immunosuppression for liver transplantation in HCV-infected patients: Mechanism-based principles
- 19 October 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 11 (11), 1343-1352
- https://doi.org/10.1002/lt.20536
Abstract
We retrospectively analyzed 42 hepatitis C virus (HCV)-infected patients who underwent cadaveric liver transplantation under two strategies of immunosuppression: (1) daily tacrolimus (TAC) throughout and an initial cycle of high-dose prednisone (PRED) with subsequent gradual steroid weaning, or (2) intraoperative antithymocyte globulin (ATG) and daily TAC that was later space weaned. After 36 +/- 4 months, patient and graft survival in the first group was 18/19 (94.7%) with no examples of clinically serious HCV recurrence. In the second group, the three-year patient survival was 12/23 (52%), and graft survival was 9/23 (39%); accelerated recurrent hepatitis was the principal cause of the poor results. The data were interpreted in the context of a recently proposed immunologic paradigm that is equally applicable to transplantation and viral immunity. In the framework of this paradigm, the disparate hepatitis outcomes reflected different equilibria reached under the two immunosuppression regimens between the relative kinetics of viral distribution (systemically and in the liver) and the slowly recovering HCV-specific T-cell response. As a corollary, the aims of treatment of the HCV-infected liver recipients should be to predict, monitor, and equilibrate beneficial balances between virus distribution and the absence of an immunopathologic antiviral T-cell response. In this view, favorable equilibria were accomplished in the nonweaned group of patients but not in the weaned group. In conclusion, since the anti-HCV response is unleashed when immunosuppression is weaned, treatment protocols that minimize disease recurrence in HCV-infected allograft recipients must balance the desire to reduce immunosuppression or induce allotolerance with the need to prevent antiviral immunopathology.Keywords
This publication has 39 references indexed in Scilit:
- Management of hepatitis C virus infection in the setting of liver transplantationLiver Transplantation, 2005
- Commentary: T cells get by with a little help from their friendsEuropean Journal of Immunology, 2004
- Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1Transplantation, 2003
- Impact of immunosuppressive therapy on recurrence of hepatitis CLiver Transplantation, 2002
- The discovery of MHC restrictionImmunology Today, 1997
- T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDSImmunology Today, 1994
- Effector T‐Cell Induction and T‐Cell Memory versus Peripheral Deletion of T CellsImmunological Reviews, 1993
- Hepatitis C virus reinfection in allografts after orthotopic liver transplantationHepatology, 1992
- Liver, Kidney, and Thoracic Organ Transplantation Under FK 506Annals of Surgery, 1990
- Liver Transplantation with Use of Cyclosporin a and PrednisoneNew England Journal of Medicine, 1981